Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma

Oncogene volume 26, pages 3699–3703 (2007)Cite this article

Abstract

Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with 90Y has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. (2000). Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342: 613–619.

    Article  CAS  PubMed  Google Scholar 

  • Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA et al. (2006). Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941–5946.

    Article  CAS  PubMed  Google Scholar 

  • Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J et al. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705–8708.

    Article  CAS  PubMed  Google Scholar 

  • Depper JM, Leonard WJ, Kronke M, Noguchi PD, Cunningham RE, Waldmann TA et al. (1984). Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 133: 3054–3061.

    CAS  PubMed  Google Scholar 

  • Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C et al. (2000). The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 69: 1867–1872.

    Article  CAS  PubMed  Google Scholar 

  • Jeang KT . (2001). Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 12: 207–217.

    Article  CAS  PubMed  Google Scholar 

  • Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C . (1990). Anti-Tac-H a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50: 1495–1502.

    CAS  PubMed  Google Scholar 

  • Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S et al. (2000). Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622–1636.

    Article  CAS  PubMed  Google Scholar 

  • Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S et al. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin-2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448–458.

    Article  CAS  PubMed  Google Scholar 

  • Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS et al. (1998). Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 44: 942–947.

    Article  CAS  PubMed  Google Scholar 

  • Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ et al. (1984). Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626–631.

    Article  CAS  PubMed  Google Scholar 

  • Leonard WJ, Depper JM, Kronke M, Robb RJ, Waldmann TA, Greene WC . (1985). The human receptor for T-cell growth factor. Evidence for variable post-translational processing phosphorylation sulfation and the ability of precursor forms of the receptor to bind T-cell growth factor. J Biol Chem 260: 1872–1880.

    CAS  PubMed  Google Scholar 

  • Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC . (1982). A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: partial characterization of the receptor. Nature 300: 267–269.

    Article  CAS  PubMed  Google Scholar 

  • Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB . (2005). Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174: 5187–5191.

    Article  CAS  PubMed  Google Scholar 

  • Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS . (2003). Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 102: 3584–3586.

    Article  CAS  PubMed  Google Scholar 

  • Morris JC, Waldmann TA . (2000). Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59 (Suppl 1): i109–i114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nashan B, Light S, Hardie IR, Lin A, Johnson JR . (1999). Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67: 110–115.

    Article  CAS  PubMed  Google Scholar 

  • Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van VP et al. (1999). Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96: 7462–7466.

    Article  CAS  PubMed  Google Scholar 

  • O'Mahony D, Morris JC, Carrasquillo JA, Le N, Paik CH, Whatley M et al. (2006). Phase I/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in CD25-expressing malignancies. J Nucl Med 47: 98P.

    Google Scholar 

  • Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK et al. (2000). IL-2R alpha directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2R alpha interaction. Cancer Res 60: 6977–6984.

    CAS  PubMed  Google Scholar 

  • Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86: 10029–10033.

    Article  CAS  PubMed  Google Scholar 

  • Rubin LA, Nelson DL . (1990). The soluble interleukin-2 receptor: biology function and clinical application. Ann Intern Med 113: 619–627.

    Article  CAS  PubMed  Google Scholar 

  • Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230–238.

    Article  CAS  PubMed  Google Scholar 

  • Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ . (1986). Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234: 859–863.

    Article  CAS  PubMed  Google Scholar 

  • Sloand EM, Scheinberg P, Maciejewski J, Young NS . (2006). Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 144: 181–185.

    Article  CAS  PubMed  Google Scholar 

  • Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K et al. (1996). The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14: 179–205.

    Article  CAS  PubMed  Google Scholar 

  • Tan C, Waldmann TA . (2002). Proteasome inhibitor PS-341 a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62: 1083–1086.

    CAS  PubMed  Google Scholar 

  • Tsudo M, Kozak RW, Goldman CK, Waldmann TA . (1986). Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 83: 9694–9698.

    Article  CAS  PubMed  Google Scholar 

  • Uchiyama T, Broder S, Waldmann TA . (1981a). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126: 1393–1397.

    CAS  PubMed  Google Scholar 

  • Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA . (1981b). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells II. Expression of Tac antigen on activated cytotoxic killer T cells suppressor cells and on one of two types of helper T cells. J Immunol 126: 1398–1403.

    CAS  PubMed  Google Scholar 

  • Uchiyama T, Yodoi J, Sagawa K, Takatuski K, Uchino H . (1977). Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481–492.

    CAS  PubMed  Google Scholar 

  • Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. (1998). Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: daclizumab triple therapy study group. N Eng J Med 338: 161–165.

    Article  CAS  Google Scholar 

  • Waldmann TA . (1986). The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232: 727–732.

    Article  CAS  PubMed  Google Scholar 

  • Waldmann TA . (1989). The multi-subunit interleukin-2 receptor. Annu Rev Biochem 58: 875–911.

    Article  CAS  PubMed  Google Scholar 

  • Waldmann TA . (2003). The meandering 45-year odyssey of a clinical immunologist. Annu Rev Immunol 21: 1–27.

    Article  CAS  PubMed  Google Scholar 

  • Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB et al. (1988). Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805–1816.

    CAS  PubMed  Google Scholar 

  • Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA et al. (1995). Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86: 4063–4075.

    CAS  PubMed  Google Scholar 

  • Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R et al. (1993). The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 82: 1701–1712.

    CAS  PubMed  Google Scholar 

  • Wiseman LR, Faulds D . (1999). Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 58: 1029–1042.

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS et al. (2006). The anti-CD25 monoclonal antibody 7G7/B6, armed with the {alpha}-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 66: 8227–8232.

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW et al. (2004). Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 64: 5825–5829.

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA . (2005). Combination of therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 105: 1231–1236.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Intramural Research Program of the National Cancer Institute, NIH. All animal studies were approved by the Animal Care and Use Committee of the National Cancer Institute (NCI) and all clinical investigations received prior approach by the IRB, NCI.

Author information

Authors and Affiliations

  1. Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA

    T A Waldmann

Authors
  1. T A Waldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T A Waldmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waldmann, T. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26, 3699–3703 (2007). https://doi.org/10.1038/sj.onc.1210368

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210368

Keywords

This article is cited by

Search

Advanced search

Quick links